Full Press Release Details
BrainStorm Reports Outstanding ALS Interim Clinical Trial
NEW YORK & PETACH TIKVA, Israel -- (Business Wire) -- BrainStorm
Cell Therapeutics (OTC:BCLI) announced today that it has completed the planned interim safety review of its Phase I/II ALS (Amyotrophic
Lateral Sclerosis) clinical trial, indicating that autologous transplantation of the Company's cell therapy was well-tolerated,
appears to be safe for use, and did not present any undue risks to the study participants.
"We are very encouraged by the positive results of our
first cohort of 12 patients," said Professor Dimitrios Karussis of the Neurology Department at Hadassah Medical Center Jerusalem
and Principal Investigator of the trial. "This important safety and tolerability data are reassuring as we progress to the
next half of this trial. Although this is an interim safety summary report documenting achievement of the study's primary endpoint,
we cannot ignore some possible promising indications of clinical efficacy observed in single patients, such as a tendency towards
improvement in some of the major ALS Functional Rating Scale variables."
The company is also happy to report that in some patients this
pilot study demonstrated a tendency toward stabilization in some parameters in the ALS Functional Rating Scale.
The trial, which is designed to evaluate the safety and preliminary
efficacy of BrainStorm's proprietary NurOwn cell therapy (bone marrow-derived, autologous, differentiated mesenchymal stromal
cells) is being conducted at the Hadassah Medical Center in Jerusalem, Israel. The company submitted the positive interim safety
report to the Israeli Ministry of Health.
The interim data was reported on the first group of patients,
all of whom suffer from early stage or progressive ALS, also known as Lou Gehrig's disease. All patients enrolled were transplanted
with NurOwn either intramuscularly or intrathecally.
Professor Robert Brown, Chair of Neurology at the University
of Massachusetts Medical School and a world renowned expert in neuromuscular genetics and ALS, added, "This interim report
clearly documents that Brainstorm's NurOwn stem cell therapy is safe. We are absolutely delighted that, with these data in
hand, Brainstorm is now moving forward into expanded studies involving trials here in Boston, Massachusetts."
"BrainStorm is conducting an important Phase I/II clinical
trial to bring this potential therapy forward for patients with ALS," stated Professor Merit Cudkowicz, Chair of the Neurological
Department at Massachusetts General Hospital and ALS expert. "The safety results are a huge step in the right direction in
finding the cure for ALS. The interim results demonstrate that Brainstorm's NurOwn stem cell therapy at dosage tested is
safe. The next steps are to explore additional dosages and a Phase II safety and preliminary efficacy study that we plan to assist
indesigning. We look forward to working with BrainStorm on ALS," continued Professor Cudkowicz.
Dr. Adrian Harel, CEO of BrainStorm, commented, "We are
very pleased and excited with this interim safety report. Our Phase I/II human clinical trial represents the first time ever that
autologous, bone marrow-derived, neurotrophic factor-secreting stem cells have been transplanted as a potential therapeutic agent
Orphan-drug designation for NurOwn has been granted by
the US Food and Drug Administration (FDA), and BrainStorm is awaiting FDA approval to expand its ALS clinical development to the
United States. The Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and
Massachusetts General Hospital to begin ALS human clinical trials at these institutions.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company
engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the
treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology
through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of
Tel-Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data
and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm
Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms
and phrases such as "may", "should", "would", "could", "will", "expect",
"likely", "believe", "plan", "estimate", "predict", "potential",and
similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include,
without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence
on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific
consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form
10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be
considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking
statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
BrainStorm Cell Therapeutics Inc. (OTC: BCLI)
Adrian Harel, Ph.D., CEO
ACC International Holdings
Phone + 972 2 652-2363
Fax + 972 2 652 2919
Email: clebovits@acc-holdings.com